These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 32707894)

  • 41. B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma.
    Tai YT; Anderson KC
    Expert Opin Biol Ther; 2019 Nov; 19(11):1143-1156. PubMed ID: 31277554
    [No Abstract]   [Full Text] [Related]  

  • 42. Monoclonal antibodies as an addition to current myeloma therapy strategies.
    Jullien M; Touzeau C; Moreau P
    Expert Rev Anticancer Ther; 2021 Jan; 21(1):33-43. PubMed ID: 33052750
    [TBL] [Abstract][Full Text] [Related]  

  • 43. BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma.
    Yang J; Zhou W; Li D; Niu T; Wang W
    Cancer Lett; 2023 Jan; 553():215949. PubMed ID: 36216149
    [TBL] [Abstract][Full Text] [Related]  

  • 44. New and emerging pharmacotherapies for the management of multiple myeloma.
    Moore DC; Oxencis CJ; Shank BR
    Am J Health Syst Pharm; 2022 Jul; 79(14):1137-1145. PubMed ID: 35333922
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma.
    Poels R; Drent E; Lameris R; Katsarou A; Themeli M; van der Vliet HJ; de Gruijl TD; van de Donk NWCJ; Mutis T
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33499253
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.
    Raje N; Berdeja J; Lin Y; Siegel D; Jagannath S; Madduri D; Liedtke M; Rosenblatt J; Maus MV; Turka A; Lam LP; Morgan RA; Friedman K; Massaro M; Wang J; Russotti G; Yang Z; Campbell T; Hege K; Petrocca F; Quigley MT; Munshi N; Kochenderfer JN
    N Engl J Med; 2019 May; 380(18):1726-1737. PubMed ID: 31042825
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Engineered T cells secreting anti-BCMA T cell engagers control multiple myeloma and promote immune memory in vivo.
    Díez-Alonso L; Falgas A; Arroyo-Ródenas J; Romencín PA; Martínez A; Gómez-Rosel M; Blanco B; Jiménez-Reinoso A; Mayado A; Pérez-Pons A; Aguilar-Sopeña Ó; Ramírez-Fernández Á; Segura-Tudela A; Perez-Amill L; Tapia-Galisteo A; Domínguez-Alonso C; Rubio-Pérez L; Jara M; Solé F; Hangiu O; Almagro L; Albitre Á; Penela P; Sanz L; Anguita E; Valeri A; García-Ortiz A; Río P; Juan M; Martínez-López J; Roda-Navarro P; Martín-Antonio B; Orfao A; Menéndez P; Bueno C; Álvarez-Vallina L
    Sci Transl Med; 2024 Feb; 16(734):eadg7962. PubMed ID: 38354229
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Role of CAR-T in multiple myeloma and coordination between referring and treating centers].
    Yoshihara S
    Rinsho Ketsueki; 2024; 65(9):1042-1048. PubMed ID: 39358259
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Belantamab mafodotin in the treatment of relapsed or refractory multiple myeloma.
    Sheikh S; Lebel E; Trudel S
    Future Oncol; 2020 Dec; 16(34):2783-2798. PubMed ID: 32875817
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial.
    Yan Z; Cao J; Cheng H; Qiao J; Zhang H; Wang Y; Shi M; Lan J; Fei X; Jin L; Jing G; Sang W; Zhu F; Chen W; Wu Q; Yao Y; Wang G; Zhao J; Zheng J; Li Z; Xu K
    Lancet Haematol; 2019 Oct; 6(10):e521-e529. PubMed ID: 31378662
    [TBL] [Abstract][Full Text] [Related]  

  • 51. IL-18-secreting multiantigen targeting CAR T cells eliminate antigen-low myeloma in an immunocompetent mouse model.
    Ng BD; Rajagopalan A; Kousa AI; Fischman JS; Chen S; Massa A; Elias HK; Manuele D; Galiano M; Lemarquis AL; Boardman AP; DeWolf S; Pierce J; Bogen B; James SE; van den Brink MRM
    Blood; 2024 Jul; 144(2):171-186. PubMed ID: 38579288
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma.
    Schmidts A; Ormhøj M; Choi BD; Taylor AO; Bouffard AA; Scarfò I; Larson RC; Frigault MJ; Gallagher K; Castano AP; Riley LS; Cabral ML; Boroughs AC; Velasco Cárdenas RM; Schamel W; Zhou J; Mackay S; Tai YT; Anderson KC; Maus MV
    Blood Adv; 2019 Nov; 3(21):3248-3260. PubMed ID: 31698455
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma.
    Zhang L; Shen X; Yu W; Li J; Zhang J; Zhang R; Li J; Chen L
    Ann Med; 2021 Dec; 53(1):1547-1559. PubMed ID: 34459681
    [TBL] [Abstract][Full Text] [Related]  

  • 54. BCMA/CD47-directed universal CAR-T cells exhibit excellent antitumor activity in multiple myeloma.
    Lu Q; Li H; Wu Z; Zhu Z; Zhang Z; Yang D; Tong A
    J Nanobiotechnology; 2024 May; 22(1):279. PubMed ID: 38783333
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial.
    Trudel S; Lendvai N; Popat R; Voorhees PM; Reeves B; Libby EN; Richardson PG; Anderson LD; Sutherland HJ; Yong K; Hoos A; Gorczyca MM; Lahiri S; He Z; Austin DJ; Opalinska JB; Cohen AD
    Lancet Oncol; 2018 Dec; 19(12):1641-1653. PubMed ID: 30442502
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Clinical analysis of the correlation between the expression of soluble B cell maturation antigen and the efficacy of chimeric antigen receptor T cell targeting B cell maturation antigen in patients with multiple myeloma].
    Gao SQ; Mu J; Li X; Wang J; Cui R; Li JY; Sui T; Deng Q
    Zhonghua Xue Ye Xue Za Zhi; 2024 Apr; 45(4):378-382. PubMed ID: 38951066
    [No Abstract]   [Full Text] [Related]  

  • 57. Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case report.
    Madduri D; Parekh S; Campbell TB; Neumann F; Petrocca F; Jagannath S
    J Med Case Rep; 2021 Feb; 15(1):90. PubMed ID: 33608053
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
    Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
    Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
    [TBL] [Abstract][Full Text] [Related]  

  • 59. B-cell maturation antigen-specific chimeric antigen receptor T cells for multiple myeloma: Clinical experience and future perspectives.
    Sellner L; Fan F; Giesen N; Schubert ML; Goldschmidt H; Müller-Tidow C; Dreger P; Raab MS; Schmitt M
    Int J Cancer; 2020 Oct; 147(8):2029-2041. PubMed ID: 32270481
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Early Chimeric Antigen Receptor T Cell Expansion Is Associated with Prolonged Progression-Free Survival for Patients with Relapsed/Refractory Multiple Myeloma Treated with Ide-Cel: A Retrospective Monocentric Study.
    Caillot L; Sleiman E; Lafon I; Chretien ML; Gueneau P; Payssot A; Pedri R; Lakomy D; Bailly F; Guy J; Quenot JP; Avet-Loiseau H; Caillot D
    Transplant Cell Ther; 2024 Jun; 30(6):630.e1-630.e8. PubMed ID: 38458477
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.